Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRATE IIb
2023-505441-69-00Phase 3Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of regorafenib and nivolumab in gastro-oesophageal junction cancer (GOJ), gastric cancer (GC) and gastroesophageal adenocarcinoma (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Overall survival (OS) in the overall study population. Started May 2022; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
gastro-oesophageal junction cancer (GOJ)gastric cancer (GC)gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on 2023-505441-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505441-69-00.